Youssef Afifi: The Thrombocytosis–Bleeding Paradox
Youssef Afifi, Consultant of Hematology and Internal Medicine at Cleopatra Hospitals Group, Consultant of Hematology and BMT at Police Academy, shared a post on LinkedIn:
“The thrombocytosis/bleeding paradox
More platelets mean more blood clots, right?
Actually, no. In hematology, we have a fascinating phenomenon where having ‘too many’ platelets dramatically increases the risk of bleeding.
This phenomenon perfectly illustrates why hematology is not always straight forward.
In myeloproliferative neoplasms like Essential Thrombocythemia (ET), a moderate increase in platelets predictably raises the risk of thrombosis. But once that platelet count crosses an extreme threshold – typically more than 1,000,000 or 1,500,000/μL—the script flips.
The patient’s bleeding risk skyrockets.
Why does this happen?
It comes down to ‘Acquired von Willebrand Syndrome (aVWS)‘
Normally, von Willebrand Factor (vWF) acts like the biological glue that helps platelets stick to damaged blood vessels and to each other. The largest vWF molecules (high-molecular-weight multimers) are the stickiest and most effective.
When a patient has a massive overproduction of platelets, these millions of circulating platelets rapidly bind to and clear out those crucial vWF multimers.
Essentially, the sheer volume of platelets exhausts the body’s supply of its best clotting glue.
The result? A lot of functionally useless because they can’t stick together.
This is why managing extreme thrombocytosis requires nuance.
Automatically giving aspirin to a patient with a platelet count of 1.5 million to “prevent clots” can actually trigger severe gastrointestinal or mucosal bleeding.
Instead, the focus often shifts to cytoreductive therapy to bring the absolute count down, which allows the vWF levels to recover and normalizes hemostasis.”
Stay updated with Hemostasis Today.
-
Jun 18, 2026, 15:06Nihala Sharin E A: The Vital Role of Hematology in the Medical Laboratory
-
Jun 18, 2026, 14:59Maeve Crowley: Shining a Light on Venous Thromboembolism Trends in Ireland
-
Jun 18, 2026, 14:52Samwel Mikaye: Why Early Recognition of Pulmonary Embolism Matters
-
Jun 18, 2026, 14:34Alec van Gelder: From Crisis Care to Continuous Care in SCD
-
Jun 18, 2026, 14:33Zahabia Adnan: Meta-Analysis Supports Rivaroxaban as an Effective Option for Cancer-Associated VTE
-
Jun 18, 2026, 14:17Charlotte Aubin: A New Perspective on BDNF’s Influence on Hemostasis and Thrombotic Risk
-
Jun 18, 2026, 14:01Heghine Khachatryan: Improving Long-Term Outcomes in PE Through Mechanical Thrombectomy
-
Jun 18, 2026, 13:55Shumaila Ishad: Acute Coronary Syndrome – When Every Minute Matters
-
Jun 18, 2026, 13:45Ed Shovelin: Looking Forward to ISTH in Paris